The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications

Klaus Podar, Kenneth C Anderson

Research output: Journal article (peer-reviewed)Review article

311 Citations (Scopus)


Besides its role as an essential regulator of physiologic and pathologic angiogenesis, vascular endothelial growth factor (VEGF) triggers growth, survival, and migration of leukemia and multiple myeloma cells; plays a pivotal role in hematopoiesis; inhibits maturation of dendritic cells; and increases osteoclastic bone-resorbing activity as well as osteoclast chemotaxis. Dysregulation of VEGF expression and signaling pathways therefore plays an important role in the pathogenesis and clinical features of hematologic malignancies, in particular multiple myeloma. Direct and indirect targeting of VEGF and its receptors therefore may provide a potent novel therapeutic approach to overcome resistance to therapies and thereby improve patient outcome.

Original languageEnglish
Pages (from-to)1383-1395
Number of pages13
Issue number4
Publication statusPublished - 15 Feb 2005
Externally publishedYes


  • Animals
  • Hematologic Neoplasms/blood
  • Humans
  • Neovascularization, Pathologic/blood
  • Vascular Endothelial Growth Factor A/biosynthesis


Dive into the research topics of 'The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications'. Together they form a unique fingerprint.

Cite this